Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin lowers glucose production by the liver and increases insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones (GLP‑1 and GIP) that stimulate insulin release and suppress glucagon when glucose is high. Together they provide complementary mechanisms to reduce blood sugar.

The specific dose of Maymetsi is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic goals, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Maymetsi is generally not recommended during pregnancy or lactation unless the potential benefit outweighs the risk. Metformin is sometimes continued if needed, but sitagliptin lacks sufficient safety data. Clinicians should evaluate each case and discuss alternatives with the patient.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, Maymetsi adds sitagliptin, offering greater HbA1c reduction without the weight gain associated with some sulfonylureas. Unlike insulin, it is oral and does not require injection, but it may be less potent than GLP‑1 receptor agonists for weight loss.

Maymetsi tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Maymetsi is taken orally, usually once daily with the evening meal, unless otherwise directed by a healthcare professional. Swallow the tablet whole with water; do not crush or chew it, as this may affect drug absorption.

The most serious risks include metformin‑associated lactic acidosis, especially in patients with renal impairment, and rare but severe hypersensitivity reactions such as anaphylaxis. Pancreatitis and significant hepatic dysfunction have also been reported, requiring prompt medical attention.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the tablet, and in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.